

ADAP Medical Advisory Committee

July 20, 2022 Gathering Notes

1) Welcome and Rollcall

I. Welcome:

Meeting opened by Sharisse Kemp, ADAP Branch Chief

II. Introductions:

MAC Members, CDPH and Magellan introduced themselves

MAC Members in Attendance

Stephen O'Brien, Michelle Sherman, Danny Toub, Lucas Hill, David Grelotti, Laveeza Bhatti, David Lewis, Cliff Okada, Joanna Eveland, Wilbert Jordan, Glenn San Agustin

CDPH/Office of AIDS staff in Attendance

Philip Peters, Sharisse Kemp, Ann Nakamura, Becca Parks, James Vo, Alejandro Contreras

MAC Members not in Attendance

Arlet Arratoonian, Michelle Sherman

Magellan Representatives in Attendance

Jason Eugenio, Carrie Holden

2) ADAP / MAC Updates

I. Medications added to the ADAP formulary:

- Removal of the maximum 5-refill limit to non-controlled ADAP formulary medications.
- Removal of Brand Preferencing for Epclusa and Harvoni.
- Hypertension and diabetes medications are moving forward towards being added to the ADAP formulary.
- Primaquine, Priftin and Xifaxan will be added to the ADAP formulary. A management memo will be released with more information.

II. Medications removed from the ADAP formulary

- None

III. Update on the medications discussed during the March 2022 MAC meeting:

- Ethinyl estradiol and norethindrone contraceptive medications to the ADAP formulary are currently in final stages of approval.

3) Medication Discussion

- #### I. No new ARVs have received FDA approval

II. No public comments received

4) **Opportunistic Infection Treatments**

I. No new opportunistic infection discussion

5) **Magellan Rx Presentation**

I. Carrie Holden presented on:

- Antipsychotics
- Diabetes Treatment

6) **Close of Meeting**

I. The next ADAP MAC gathering is scheduled for October 19, 2022, from 7:30 a.m. to 9:00 a.m.

7) **Action Items**

Action Items	Owners
Long-acting injectable antipsychotic medications	Carrie Holden
Diabetes medication cost analysis	James Vo
Drafting a statement for prioritization of Monkeypox	James Vo